Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBI-20089
- Development stage
- Phase 2
- Lead developer
- EyePoint Pharmaceuticals
- Modality
- Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Administration
- Ophthalmic, Intravitreal
01
Overview
IBI-20089 is a sustained-release intravitreal liquid drug delivery system containing triamcinolone acetonide, a synthetic corticosteroid. Developed by Icon Bioscience using its proprietary Verisome technology, the drug is designed for the treatment of cystoid macular edema (CME) associated with retinal vein occlusion (RVO). Upon injection into the vitreous, the Verisome system forms a semi-opaque, biodegradable depot (often appearing as a milky ball) that provides controlled and sustained release of the active ingredient over an extended period, potentially lasting up to one year. This delivery method aims to maintain therapeutic levels of triamcinolone while reducing the frequency of injections and minimizing the side effects typically associated with traditional intravitreal steroid suspensions.
- Other names
- Triamcinolone acetonide VerisomeVerisome TA
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on IBI-20089.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBI-20089.